At the 10x Genomics Atera World Tour 2026 in Paris, Explicyte presented two case studies tackling a question every spatial biology team faces: how do you extract more biological value from FFPE tumor samples while keeping turnaround time and cost under control?
The challenge: spatial transcriptomics at scale
Single-cell spatial transcriptomics is now a production tool in oncology, but scaling Xenium campaigns runs into the same three constraints: a finite panel size, per-sample cost, and turnaround time. Our “Smarter Xenium” approach tackles all three on real FFPE tumor cohorts.
Case study 1 — Xenium beyond 5K
On FFPE pancreatic cancer samples, we integrated matched scRNA-seq data with Xenium to recover biology the 5K panel alone cannot resolve, sharpening cell annotation while keeping full spatial context.
Case study 2 — Sample multiplexing with Bioptimus
With AI company Bioptimus, we doubled the number of FFPE samples per Xenium slide and compared the results head-to-head with the standard format: the data held up across QC, cell-type proportions and gene expression.
Bring this to your next spatial study
Planning a Xenium or Visium HD study on FFPE tissue? Talk to our spatial biology team.
About Explicyte
Explicyte is a preclinical and translational CRO specializing in precision oncology, with 10+ years of experience and 40+ peer-reviewed publications. As a 10x Genomics Certified Service Provider across Chromium X, Visium HD and Xenium, we help pharma and biotech sponsors turn FFPE tumor samples into actionable insight, from target and biomarker discovery to biospecimen analysis in early-phase clinical trials.
